Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
36 studies found for:    Neuromyelitis Optica
Show Display Options
Rank Status Study
21 Completed A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
Conditions: Neuromyelitis Optica;   Myelitis, Transverse;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System
Intervention: Drug: Mitoxantrone
22 Completed
Has Results
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Bevacizumab
23 Recruiting Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
Conditions: Multiple Sclerosis;   Neuromyelitis Optica
Intervention: Biological: Tolerogenic Dendritic cells loaded with myelin peptides
24 Recruiting A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Eculizumab
25 Enrolling by invitation An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Biological: eculizumab
26 Recruiting Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Condition: Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Interventions: Drug: SA237;   Drug: Placebo
27 Recruiting Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD
Conditions: Neuromyelitis Optica (NMO);   NMO Spectrum Disorder (NMOSD)
Interventions: Drug: SA237;   Drug: Placebo
28 Recruiting The French Multiple Sclerosis Registry
Conditions: Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorders
Intervention:
29 Terminated A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
Conditions: Myelitis, Transverse;   Neuromyelitis Optica
Interventions: Drug: Intravenous Methylprednisolone;   Drug: Intravenous Immunoglobulin
30 Active, not recruiting Biobank For MS And Other Demyelinating Diseases
Conditions: Multiple Sclerosis;   Transverse Myelitis;   Neuromyelitis Optica;   Acute Disseminated Encephalomyelitis;   Optic Neuritis
Intervention:
31 Active, not recruiting Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Conditions: Transverse Myelitis;   Neuromyelitis Optica;   Idiopathic Transverse Myelitis;   Myelitis NOS
Interventions: Drug: Dalfampridine;   Drug: Placebo
32 Recruiting The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset
Condition: Optic Neuritis
Intervention: Biological: blood test of anti-AQP4 antibody
33 Recruiting Optical Coherence Tomography and Optic Neuritis (OCTON)
Condition: Optical Neuritis
Intervention:
34 Unknown  Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Conditions: Acute Disseminated Encephalomyelitis;   Devic's Syndrome;   Marburg's Variant of Multiple Sclerosis;   Balo's Concentric Sclerosis;   Acute Transverse Myelitis
Intervention: Procedure: Plasma exchange
35 Recruiting Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients
Conditions: Multiple Sclerosis;   Systemic Sclerosis
Intervention: Other: Blood sample collection
36 Recruiting Stem Cell Ophthalmology Treatment Study
Conditions: Retinal Disease;   Macular Degeneration;   Hereditary Retinal Dystrophy;   Optic Nerve Disease;   Glaucoma
Interventions: Procedure: RB (Retrobulbar);   Procedure: ST (Subtenon);   Procedure: IV (Intravenous);   Procedure: IVIT (Intravitreal);   Procedure: IO (Intraocular)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page   
Study has passed its completion date and status has not been verified in more than two years.